Richard B. Wilber
- Epidemiology top 0.5%
- Hepatology top 0.2%
- Infectious Diseases top 2%
- Pharmacology top 5%
- Virology top 5%
- Co-authors
- Richard J. ColonnoAnne CrossZachary GoodmanTing‐Tsung ChangAnna S. LokDeborah DeHertoghJose D. SollanoRichard C. Zink
- Topics
- Hepatitis B Virus Studies (13 papers)Antibiotics Pharmacokinetics and Efficacy (11 papers)Hepatitis C virus research (11 papers)
- Cited by
- HepatologyEpidemiologyVirology
- Partner nations
- United StatesGermanyChina
In The Last Decade
Richard B. Wilber
32 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 75
- Epidemiology 2.9k
- Hepatology 2.7k
- Infectious Diseases 616
- Pharmacology 193
- Virology 175
Countries citing papers authored by Richard B. Wilber
This map shows the geographic impact of Richard B. Wilber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard B. Wilber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard B. Wilber more than expected).
Fields of papers citing papers by Richard B. Wilber
This network shows the impact of papers produced by Richard B. Wilber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard B. Wilber. The network helps show where Richard B. Wilber may publish in the future.
Co-authorship network of co-authors of Richard B. Wilber
This figure shows the co-authorship network connecting the top 25 collaborators of Richard B. Wilber. A scholar is included among the top collaborators of Richard B. Wilber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard B. Wilber. Richard B. Wilber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #breakdown → | 607 |
| 2 | 146 | |
| 3 | 10 | |
| 4 | 7 | |
| 5 | Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis Bbreakdown → | 900 |
| 6 | A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis Bbreakdown → | 1064 |
| 7 | Entecavir (ETV) vs. Adefovir (ADV): HBV DNA reduction of viral load in chronically infected HBeAg(+) nucleoside naive adults in a 12-week | 1 |
| 8 | 203 | |
| 9 | 0 | |
| 10 | 20 | |
| 11 | 16 | |
| 12 | 16 | |
| 13 | 12 | |
| 14 | Cefprozil versus cefaclor in the treatment of mild to moderate skin and skin-structure infections. The Cefprozil Multicenter Study Group. | 16 |
| 15 | 20 | |
| 16 | 13 | |
| 17 | 18 | |
| 18 | 21 | |
| 19 | 40 | |
| 20 | 1 |
About Richard B. Wilber
Richard B. Wilber is a scholar working on Hepatology, Pharmacology and Infectious Diseases, having authored 33 papers that have together received 3.4k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (13 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Hepatitis C virus research (11 papers). The work is most often cited by research in Hepatology (2.7k citations), Epidemiology (2.9k citations) and Virology (175 citations). Richard B. Wilber has collaborated with scholars based in United States, Germany and China. Frequent co-authors include Richard J. Colonno, Anne Cross, Zachary Goodman, Ting‐Tsung Chang, Anna S. Lok, Deborah DeHertogh, Jose D. Sollano, Richard C. Zink, Ching‐Lung Lai and Daniel Shouval. Their work appears in journals such as New England Journal of Medicine, JAMA and Gastroenterology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.